Time to 12-month remission and treatment failure for generalised and unclassified epilepsy

被引:16
作者
Bonnett, Laura J. [1 ]
Smith, Catrin Tudur [1 ]
Smith, David [2 ]
Williamson, Paula R. [1 ]
Chadwick, David [2 ]
Marson, Anthony G. [3 ]
机构
[1] Univ Liverpool, Dept Biostat, Liverpool L9 7LJ, Merseyside, England
[2] Walton Ctr Fdn NHS Trust, Dept Neurol, Liverpool, Merseyside, England
[3] Univ Liverpool, Dept Mol & Clin Pharmacol, Liverpool L9 7LJ, Merseyside, England
基金
美国国家卫生研究院;
关键词
MULTICENTER COMPARATIVE TRIAL; SODIUM VALPROATE; FRACTIONAL POLYNOMIALS; ANTIEPILEPTIC DRUGS; CARBAMAZEPINE; MODELS; RISK; PHENOBARBITONE; LAMOTRIGINE; PREGNANCY;
D O I
10.1136/jnnp-2013-306040
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives To develop prognostic models for time to 12-month remission and time to treatment failure after initiating antiepileptic drug monotherapy for generalised and unclassified epilepsy. Methods We analysed data from the Standard and New Antiepileptic Drug (arm B) study, a randomised trial that compared initiating treatment with lamotrigine, topiramate and valproate in patients diagnosed with generalised or unclassified epilepsy. Multivariable regression modelling was used to investigate how clinical factors affect the probability of achieving 12-month remission and treatment failure. Results Significant factors in the multivariable model for time to 12-month remission were having a relative with epilepsy, neurological insult, total number of tonic-clonic seizures before randomisation, seizure type and treatment. Significant factors in the multivariable model for time to treatment failure were treatment history (antiepileptic drug treatment prior to randomisation), EEG result, seizure type and treatment. Conclusions The models described within this paper can be used to identify patients most likely to achieve 12-month remission and most likely to have treatment failure, aiding individual patient risk stratification and the design and analysis of future epilepsy trials.
引用
收藏
页码:603 / 610
页数:8
相关论文
共 31 条
[1]  
[Anonymous], 2003, Modelling Survival Data in Medical Research
[2]  
[Anonymous], 2008, Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables
[3]  
[Anonymous], STAT SCI, DOI DOI 10.1214/ss/1177013607
[4]   Prognostic factors for time to treatment failure and time to 12 months of remission for patients with focal epilepsy: post-hoc, subgroup analyses of data from the SANAD trial [J].
Bonnett, Laura ;
Smith, Catrin Tudur ;
Smith, David ;
Williamson, Paula ;
Chadwick, David ;
Marson, Anthony G. .
LANCET NEUROLOGY, 2012, 11 (04) :331-340
[5]   REMISSION OF EPILEPSY - RESULTS FROM THE NATIONAL GENERAL-PRACTICE STUDY OF EPILEPSY [J].
COCKERELL, OC ;
JOHNSON, AL ;
SANDER, JWAS ;
HART, YM ;
SHORVON, SD .
LANCET, 1995, 346 (8968) :140-144
[6]   Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy [J].
deSilva, M ;
MacArdle, B ;
McGowan, M ;
Hughes, E ;
Stewart, J ;
Neville, BGR ;
Johnson, AL ;
Reynolds, EH .
LANCET, 1996, 347 (9003) :709-713
[7]   Ethosuximide, Valproic Acid, and Lamotrigine in Childhood Absence Epilepsy. [J].
Glauser, Tracy A. ;
Cnaan, Avital ;
Shinnar, Shlomo ;
Hirtz, Deborah G. ;
Dlugos, Dennis ;
Masur, David ;
Clark, Peggy O. ;
Capparelli, Edmund V. ;
Adamson, Peter C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (09) :790-799
[8]   A CLASS OF K-SAMPLE TESTS FOR COMPARING THE CUMULATIVE INCIDENCE OF A COMPETING RISK [J].
GRAY, RJ .
ANNALS OF STATISTICS, 1988, 16 (03) :1141-1154
[9]  
Harrell F. E., 2001, Regression modelling strategies: with applications to linear models, logistic regression, and survival analysis, DOI DOI 10.1007/978-1-4757-3462-1
[10]  
Harrell FE, 1996, STAT MED, V15, P361, DOI 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO